Osteoporosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Osteoporosis – Pipeline Review, H2 2016’, provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteoporosis

The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects

The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Osteoporosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Osteoporosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addex Therapeutics Ltd

Alethia Biotherapeutics Inc.

Alize Pharma SAS

Alkem Laboratories Ltd.

AlphaMab Co., Ltd

Alvogen Korea Co., Ltd.

Amgen Inc.

Amura Holdings Limited

Arcarios BV

BiologicsMD, Inc.

Bone Biologics, Corp.

Bone Therapeutics SA

Cellmid Limited

Chronos Therapeutics Limited

Chugai Pharmaceutical Co., Ltd.

Corium International, Inc.

Critical Pharmaceuticals Limited

Daiichi Sankyo Company, Limited

ElexoPharm GmbH

Eli Lilly and Company

EndoCeutics, Inc.

Enteris BioPharma, Inc.

Enzo Biochem, Inc.

Gador S.A.

Galapagos NV

Glide Pharmaceutical Technologies Limited

Hanmi Pharmaceuticals, Co. Ltd.

Haoma Medica Ltd.

Immunovo BV

Intas Pharmaceuticals Ltd.

Ipsen S.A.

Kaken Pharmaceutical Co., Ltd.

Lead Discovery Center GmbH

Ligand Pharmaceuticals, Inc.

Merck & Co., Inc.

Mereo Biopharma Group Plc

Midway Pharmaceuticals, Inc.

Mithra Pharmaceuticals S.A.

NIBEC

Novartis AG

Omeros Corporation

Oncobiologics, Inc.

Oscotec Inc.

OsteoGeneX Inc.

Osteologix Holdings Plc.

Paras Biopharmaceuticals Finland Oy

Pfenex Inc.

PhytoHealth Corporation

R-Pharm

Recursion Pharmaceuticals, LLC

Ribomic Inc.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Shin Poong Pharm.Co., Ltd.

Sinil Pharmaceutical Co., Ltd

STELIS Biopharma Pvt. Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

TAmiRNA GmbH

TechnoPhage SA

Terpenoid Therapeutics Inc

TSH Biopharm Corporation Limited

Uni-Bio Science Group Ltd.

Wroclawskie Centrum Badan EIT+ Sp. z o.o.

Yooyoung Pharmaceutical Co., Ltd.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Osteoporosis Overview 7

Therapeutics Development 8

Osteoporosis - Therapeutics under Development by Companies 10

Osteoporosis - Therapeutics under Investigation by Universities/Institutes 15

Osteoporosis - Pipeline Products Glance 16

Osteoporosis - Products under Development by Companies 19

Osteoporosis - Products under Investigation by Universities/Institutes 25

Osteoporosis - Companies Involved in Therapeutics Development 26

Osteoporosis - Therapeutics Assessment 90

Drug Profiles 102

Osteoporosis - Dormant Projects 253

Osteoporosis - Discontinued Products 265

Osteoporosis - Product Development Milestones 267

Appendix 282

List of Tables

List of Tables

Number of Products under Development for Osteoporosis, H2 2016 21

Number of Products under Development for Osteoporosis – Comparative Analysis, H2 2016 22

Number of Products under Development by Companies, H2 2016 23

Number of Products under Development by Companies, H2 2016 (Contd..1) 24

Number of Products under Development by Companies, H2 2016 (Contd..2) 25

Number of Products under Development by Companies, H2 2016 (Contd..3) 26

Number of Products under Development by Companies, H2 2016 (Contd..4) 27

Number of Products under Investigation by Universities/Institutes, H2 2016 28

Comparative Analysis by Late Stage Development, H2 2016 29

Comparative Analysis by Clinical Stage Development, H2 2016 30

Comparative Analysis by Early Stage Development, H2 2016 31

Products under Development by Companies, H2 2016 32

Products under Development by Companies, H2 2016 (Contd..1) 33

Products under Development by Companies, H2 2016 (Contd..2) 34

Products under Development by Companies, H2 2016 (Contd..3) 35

Products under Development by Companies, H2 2016 (Contd..4) 36

Products under Development by Companies, H2 2016 (Contd..5) 37

Products under Investigation by Universities/Institutes, H2 2016 38

Osteoporosis – Pipeline by Addex Therapeutics Ltd, H2 2016 39

Osteoporosis – Pipeline by Alethia Biotherapeutics Inc., H2 2016 40

Osteoporosis – Pipeline by Alize Pharma SAS, H2 2016 41

Osteoporosis – Pipeline by Alkem Laboratories Ltd., H2 2016 42

Osteoporosis – Pipeline by AlphaMab Co., Ltd, H2 2016 43

Osteoporosis – Pipeline by Alvogen Korea Co., Ltd., H2 2016 44

Osteoporosis – Pipeline by Amgen Inc., H2 2016 45

Osteoporosis – Pipeline by Amura Holdings Limited, H2 2016 46

Osteoporosis – Pipeline by Arcarios BV, H2 2016 47

Osteoporosis – Pipeline by BiologicsMD, Inc., H2 2016 48

Osteoporosis – Pipeline by Bone Biologics, Corp., H2 2016 49

Osteoporosis – Pipeline by Bone Therapeutics SA, H2 2016 50

Osteoporosis – Pipeline by Cellmid Limited, H2 2016 51

Osteoporosis – Pipeline by Chronos Therapeutics Limited, H2 2016 52

Osteoporosis – Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016 53

Osteoporosis – Pipeline by Corium International, Inc., H2 2016 54

Osteoporosis – Pipeline by Critical Pharmaceuticals Limited, H2 2016 55

Osteoporosis – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 56

Osteoporosis – Pipeline by ElexoPharm GmbH, H2 2016 57

Osteoporosis – Pipeline by Eli Lilly and Company, H2 2016 58

Osteoporosis – Pipeline by EndoCeutics, Inc., H2 2016 59

Osteoporosis – Pipeline by Enteris BioPharma, Inc., H2 2016 60

Osteoporosis – Pipeline by Enzo Biochem, Inc., H2 2016 61

Osteoporosis – Pipeline by Gador S.A., H2 2016 62

Osteoporosis – Pipeline by Galapagos NV, H2 2016 63

Osteoporosis – Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 64

Osteoporosis – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 65

Osteoporosis – Pipeline by Haoma Medica Ltd., H2 2016 66

Osteoporosis – Pipeline by Immunovo BV, H2 2016 67

Osteoporosis – Pipeline by Intas Pharmaceuticals Ltd., H2 2016 68

Osteoporosis – Pipeline by Ipsen S.A., H2 2016 69

Osteoporosis – Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016 70

Osteoporosis – Pipeline by Lead Discovery Center GmbH, H2 2016 71

Osteoporosis – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 72

Osteoporosis – Pipeline by Merck & Co., Inc., H2 2016 73

Osteoporosis – Pipeline by Mereo Biopharma Group Plc, H2 2016 74

Osteoporosis – Pipeline by Midway Pharmaceuticals, Inc., H2 2016 75

Osteoporosis – Pipeline by Mithra Pharmaceuticals S.A., H2 2016 76

Osteoporosis – Pipeline by NIBEC, H2 2016 77

Osteoporosis – Pipeline by Novartis AG, H2 2016 78

Osteoporosis – Pipeline by Omeros Corporation, H2 2016 79

Osteoporosis – Pipeline by Oncobiologics, Inc., H2 2016 80

Osteoporosis – Pipeline by Oscotec Inc., H2 2016 81

Osteoporosis – Pipeline by OsteoGeneX Inc., H2 2016 82

Osteoporosis – Pipeline by Osteologix Holdings Plc., H2 2016 83

Osteoporosis – Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 84

Osteoporosis – Pipeline by Pfenex Inc., H2 2016 85

Osteoporosis – Pipeline by PhytoHealth Corporation, H2 2016 86

Osteoporosis – Pipeline by R-Pharm, H2 2016 87

Osteoporosis – Pipeline by Recursion Pharmaceuticals, LLC, H2 2016 88

Osteoporosis – Pipeline by Ribomic Inc., H2 2016 89

Osteoporosis – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016 90

Osteoporosis – Pipeline by Shin Poong Pharm.Co., Ltd., H2 2016 91

Osteoporosis – Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016 92

Osteoporosis – Pipeline by STELIS Biopharma Pvt. Ltd., H2 2016 93

Osteoporosis – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 94

Osteoporosis – Pipeline by TAmiRNA GmbH, H2 2016 95

Osteoporosis – Pipeline by TechnoPhage SA, H2 2016 96

Osteoporosis – Pipeline by Terpenoid Therapeutics Inc, H2 2016 97

Osteoporosis – Pipeline by TSH Biopharm Corporation Limited, H2 2016 98

Osteoporosis – Pipeline by Uni-Bio Science Group Ltd., H2 2016 99

Osteoporosis – Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H2 2016 100

Osteoporosis – Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016 101

Osteoporosis – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 102

Assessment by Monotherapy Products, H2 2016 103

Assessment by Combination Products, H2 2016 104

Number of Products by Stage and Target, H2 2016 106

Number of Products by Stage and Mechanism of Action, H2 2016 109

Number of Products by Stage and Route of Administration, H2 2016 112

Number of Products by Stage and Molecule Type, H2 2016 114

Osteoporosis – Dormant Projects, H2 2016 266

Osteoporosis – Dormant Projects (Contd..1), H2 2016 267

Osteoporosis – Dormant Projects (Contd..2), H2 2016 268

Osteoporosis – Dormant Projects (Contd..3), H2 2016 269

Osteoporosis – Dormant Projects (Contd..4), H2 2016 270

Osteoporosis – Dormant Projects (Contd..5), H2 2016 271

Osteoporosis – Dormant Projects (Contd..6), H2 2016 272

Osteoporosis – Dormant Projects (Contd..7), H2 2016 273

Osteoporosis – Dormant Projects (Contd..8), H2 2016 274

Osteoporosis – Dormant Projects (Contd..9), H2 2016 275

Osteoporosis – Dormant Projects (Contd..10), H2 2016 276

Osteoporosis – Dormant Projects (Contd..11), H2 2016 277

Osteoporosis – Discontinued Products, H2 2016 278

Osteoporosis – Discontinued Products (Contd..1), H2 2016 279

List of Figures

List of Figures

Number of Products under Development for Osteoporosis, H2 2016 21

Number of Products under Development for Osteoporosis – Comparative Analysis, H2 2016 22

Number of Products under Development by Companies, H2 2016 23

Number of Products under Investigation by Universities/Institutes, H2 2016 28

Comparative Analysis by Late Stage Development, H2 2016 29

Comparative Analysis by Clinical Stage Development, H2 2016 30

Comparative Analysis by Early Stage Products, H2 2016 31

Assessment by Monotherapy Products, H2 2016 103

Assessment by Combination Products, H2 2016 104

Number of Products by Top 10 Targets, H2 2016 105

Number of Products by Stage and Top 10 Targets, H2 2016 105

Number of Products by Top 10 Mechanism of Actions, H2 2016 108

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 108

Number of Products by Routes of Administration, H2 2016 111

Number of Products by Stage and Routes of Administration, H2 2016 111

Number of Products by Top 10 Molecule Types, H2 2016 113

Number of Products by Stage and Top 10 Molecule Types, H2 2016 113

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports